Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: A multi-institutional study

Yasunori Nakagawa, Kenshi Suzuki, Takayuki Hirose, Takaaki Chou, Shin Fujisawa, Michiko Kida, Kensuke Usuki, Yoji Ishida, Shuichi Taniguchi, Yasuji Kouzai, Shigeru Tomoyasu, Koji Miyazaki, Masaaki Higashihara, Kiyoshi Ando, Sadao Aoki, Ayako Arai, Nobu Akiyama, Kiyohiko Hatake, Shinichiro Okamoto, Kazuo DanKazuma Ohyashiki, Akio Urabe

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.

Original languageEnglish
Pages (from-to)58-67
Number of pages10
JournalJournal of Infection and Chemotherapy
Volume17
Issue number1
DOIs
Publication statusPublished - 2011 Feb

Keywords

  • Biapenem
  • Febrile neutropenia
  • Hematopoietic diseases

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: A multi-institutional study'. Together they form a unique fingerprint.

Cite this